» Articles » PMID: 15192785

The Epidemiology of Cholangiocarcinoma

Overview
Journal Semin Liver Dis
Publisher Thieme
Specialty Gastroenterology
Date 2004 Jun 12
PMID 15192785
Citations 464
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence rates of cholangiocarcinoma (CC) vary greatly among different areas of the world, and this variation is related to distribution of risk factors. Intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) have different epidemiological features. Recent data show that the incidence and mortality rates of ICC have been increasing in several areas around the world. On the other hand, the incidence and mortality rates of ECC have been decreasing. For example, in the United States, the age-adjusted incidence rates of ICC increased by 165% from 0.32 per 100,000 in 1975 to 1979 to 0.85 per 100,000 in 1995 to 1999, whereas ECC declined by 14%. In the meantime, there has been very little improvement in long-term survival, which remains dismal (3.5%). Men are affected 1.5 times more than women are, and Asians are affected almost 2 times more than whites and blacks. There are few well-established risk factors for CC, including primary sclerosing cholangitis, liver fluke infestations, hepatolithiasis, Thorotrast exposure, and choledochal cysts. None of these risk factors can explain the recent increasing trends of ICC in the United States. Some data, however, point to a potential role for chronic liver disease, hepatitis C, and probably hepatitis B infections in the development of ICC.

Citing Articles

Choledocholithiasis as a risk factor for cholangiocarcinoma: a nationwide retrospective cohort study.

Kim J, Lee Y, Lee J, Hwang J BMC Gastroenterol. 2025; 25(1):138.

PMID: 40045214 PMC: 11883955. DOI: 10.1186/s12876-025-03746-w.


Digestive cancers: mechanisms, therapeutics and management.

Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M Signal Transduct Target Ther. 2025; 10(1):24.

PMID: 39809756 PMC: 11733248. DOI: 10.1038/s41392-024-02097-4.


Prognostic Significance of Lymphocyte-to-Monocyte Ratio in Patients With Unresectable Biliary Tract Cancer Undergoing Systemic Chemotherapy.

Suzuki H, Kuwano A, Takahira J, Tanaka K, Yada M, Motomura K Cancer Diagn Progn. 2025; 5(1):132-137.

PMID: 39758246 PMC: 11696337. DOI: 10.21873/cdp.10422.


Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized Therapy.

Ursprung S, Thaiss W, Beha J, Moller Y, Malek N, Beer M J Pers Med. 2024; 14(12).

PMID: 39728056 PMC: 11679776. DOI: 10.3390/jpm14121143.


New direction: identification of immunoinflammatory subtypes and potential therapeutic targets for cholangiocarcinoma.

Chen Z, Song H, Tang J, Liu J, Xia L Discov Oncol. 2024; 15(1):726.

PMID: 39612077 PMC: 11607260. DOI: 10.1007/s12672-024-01628-3.